TY  - JOUR
A1  - Bergmann, Lothar
A1  - Enzmann, Harald
A1  - Thirstrup, Steffen
A1  - Schweim, Janna K.
A1  - Widera, Ilana
A1  - Zwierzina, Heinz
T1  - Access to innovative oncology medicines in Europe
T2  - Annals of oncology
N2  - This article intends to give an overview about developments in European Regulatory and Health Technology Assessment (HTA) of new cancer drugs. As background information, it will refer to an overview article by Bergmann et al. [1], which pointed out the status and the limitations of the current system. The authors discussed possible steps to improve the interface between regulators and HTA bodies but stated that this alone will not be sufficient to overcome heterogeneous HTA assessments between HTA agencies. Major issues and challenges for the foreseeable future will be to overcome the heterogeneity of patient access decisions of pharmaceutical payers across Europe which is due to (i) considerably different scientific approaches and methodology to the more or less formal evaluation of cost-effectiveness; (ii) differing health priorities across the countries that reflect historically developed cultural differences and values or different unmet medical needs and (iii) different economic strengths among nations, regions and locales that necessarily drive health care budgetary decisions. The authors consider that this needs a science-based common position on methodology, greater commitments by politicians and health care decision makers to ensure equal access for patients across the EU to anti-tumour medicines. ...
Y1  - 2015
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50591
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-505914
SN  - 1569-8041
SN  - 0923-7534
N1  - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
VL  - 27.2016
IS  - 2
SP  - 353
EP  - 356
PB  - Oxford Univ. Press
CY  - Oxford
ER  -